Vemurafenib Recruiting Phase 1 / 2 Trials for BRAF-mutated Metastatic Melanoma / Melanoma / Metastatic Melanoma / V600EBRAF-mutated Metastatic Melanoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT02818023Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma